Literature DB >> 18645526

Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis.

Stefan Lüth1, Johannes Herkel, Stephan Kanzler, Christian Frenzel, Peter R Galle, Hans P Dienes, Christoph Schramm, Ansgar W Lohse.   

Abstract

GOALS/
BACKGROUND: Disease activity and response to treatment in autoimmune hepatitis is assessed best by liver biopsy, which does not suit for regular disease monitoring. It is frequent clinical practice to follow disease by assessment of serologic markers. Here, we assessed the diagnostic fidelity of this clinical practice. STUDY: One hundred thirty-one biopsies from 82 patients with autoimmune hepatitis were analyzed for histologic activity. Serum samples, taken at the time of biopsy, were analyzed for aminotransferases [alanine aminotransferase (ALT), aspartate aminotransferase], IgG, and gamma-globulin levels and compared with histology.
RESULTS: All serum parameters were significantly associated with histologic activity (P<0.0075); ALT and IgG were most complementary. Presence of both elevated ALT and IgG were associated with high inflammatory activity (histologic activity scores >/=6) with 99% sensitivity. Elevation of either IgG or ALT was associated with residual inflammatory activity in almost all patients. Histologic remission is reliably indicated by normalization of both serum parameters, but about half of the patients with normal serum parameters still showed residual histologic activity of histologic activity index (HAI) 4 or 5. However, our patients with HAI scores 4 or 5 were at significantly lower risk of fibrosis progression than patients with scores >/=6 (P<0.02; odds ratio 14.2).
CONCLUSIONS: Histologic activity seems to be reliably indicated by elevated serum parameters. Normalization of serum parameters is not a reliable marker for complete histologic remission (HAI 1 to 3); however, normalized serum parameters identified patients at low risk of fibrosis progression. Thus, the common clinical practice of disease monitoring by serum markers seems to be suitable for regular follow-up.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18645526     DOI: 10.1097/MCG.0b013e318154af74

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  27 in total

Review 1.  Autoantibodies as prognostic markers in autoimmune liver disease.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-05-13       Impact factor: 3.199

2.  [Autoimmune liver diseases].

Authors:  N Pannicke; C Schramm; A W Lohse
Journal:  Internist (Berl)       Date:  2012-08       Impact factor: 0.743

Review 3.  Management of Difficult Cases of Autoimmune Hepatitis.

Authors:  Craig Lammert; Veronica M Loy; Kiyoko Oshima; Samer Gawrieh
Journal:  Curr Gastroenterol Rep       Date:  2016-02

Review 4.  Difficult treatment decisions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

Review 5.  Challenges in the diagnosis and management of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Can J Gastroenterol       Date:  2013-09       Impact factor: 3.522

Review 6.  Autoimmune hepatitis.

Authors:  Giorgina Mieli-Vergani; Diego Vergani
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-05-03       Impact factor: 46.802

7.  Long-Term Prognostic Significance of Persisting Histological Activity Despite Biochemical Remission in Autoimmune Hepatitis.

Authors:  Harpreet K Dhaliwal; Barbara S Hoeroldt; Asha K Dube; Elaine McFarlane; James C E Underwood; Mohammed A Karajeh; Dermot Gleeson
Journal:  Am J Gastroenterol       Date:  2015-05-26       Impact factor: 10.864

Review 8.  [Autoimmune liver diseases].

Authors:  S Lüth; C Weiler-Normann; C Schramm; A W Lohse
Journal:  Internist (Berl)       Date:  2009-03       Impact factor: 0.743

9.  Treatment of autoimmune liver disease: current and future therapeutic options.

Authors:  Palak J Trivedi; Gideon M Hirschfield
Journal:  Ther Adv Chronic Dis       Date:  2013-05       Impact factor: 5.091

Review 10.  Auto immune hepatitis.

Authors:  Nicole Mf van Gerven; Ynto S de Boer; Chris Jj Mulder; Carin Mj van Nieuwkerk; Gerd Bouma
Journal:  World J Gastroenterol       Date:  2016-05-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.